Skip to main content

Table 2 Clinicopathologic characteristics of patients stratified by both neoadjuvant and adjuvant chemotherapy

From: Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Parameters

With preoperative chemotherapy (n = 122)

P value

Without preoperative chemotherapy (n = 142)

P value

With ACT (n, %)

Without ACT (n, %)

With ACT (n, %)

Without ACT (n, %)

Number of patients

98

24

 

102

40

 

Age, years

 ≤ 60

69 (70.4)

16 (66.7)

0.721

60 (58.8)

19 (47.5)

0.222

 > 60

29 (29.6)

8 (33.3)

 

42 (41.2)

21 (52.5)

 

Sex

 Male

65 (66.3)

17 (70.8)

0.673

63 (61.8)

26 (65.0)

0.720

 Female

33 (33.7)

7 (29.2)

 

39 (38.2)

14 (35.0)

 

Primary tumor location

 Colon

55 (56.1)

15 (62.5)

0.571

71 (69.6)

22 (55.0)

0.100

 Rectum

43 (43.9)

9 (37.5)

 

31 (30.4)

18 (45.0)

 

Primary tumor differentiation

 Well to moderate

72 (73.5)

20 (83.3)

0.315

83 (81.4)

31 (77.5)

0.602

 Poor

26 (26.5)

4 (16.7)

 

19 (18.6)

9 (22.5)

 

T stagea

 1–3

50 (53.2)

12 (54.5)

0.909

72 (77.4)

23 (67.6)

0.261

 4

44 (46.8)

10 (45.5)

 

21 (22.6)

11 (32.4)

 

N stageb

 0

41 (45.6)

12 (54.5)

0.449

37 (40.2)

13 (38.2)

0.840

 1–2

49 (54.4)

10 (45.5)

 

55 (59.8)

21 (61.8)

 

Timing of metastasis

 Synchronous

74 (75.5)

15 (62.5)

0.198

62 (60.8)

20 (50.0)

0.242

 Metachronous

24 (24.5)

9 (37.5)

 

40 (39.2)

20 (50.0)

 

Number of metastatic tumors

 1

29 (29.6)

9 (37.5)

0.453

73 (71.6)

29 (72.5)

0.912

 2–5

69 (70.4)

15 (62.5)

 

29 (28.4)

11 (27.5)

 

Metastases diameter (cm)c

 ≤ 3

59 (62.1)

14 (58.3)

0.735

75 (73.5)

25 (64.1)

0.270

 > 3

36 (37.9)

10 (41.7)

 

27 (26.5)

14 (35.9)

 

Preoperative CEA (ng/mL)d

 ≤ 50

78 (82.1)

17 (81.0)

0.901

78 (81.3)

27 (69.2)

0.128

 > 50

17 (17.9)

4 (19.0)

 

18 (18.8)

12 (30.8)

 

Preoperative CA19-9 (U/mL)e

 ≤ 35

70 (76.9)

15 (75.0)

1.000

58 (61.1)

23 (62.2)

0.906

 > 35

21 (23.1)

5 (25.0)

 

37 (38.9)

14 (37.8)

 

MSKCC-CRSf

 0–2

54 (63.5)

9 (47.4)

0.193

73 (83.0)

26 (78.8)

0.597

 3–5

31 (36.5)

10 (52.6)

 

15 (17.0)

7 (21.2)

 

Preoperative chemotherapy regimen

 FOLFOX + XELOX

61 (62.2)

18 (75.0)

0.503

   

 FOLFIRI

31 (31.6)

5 (20.8)

    

 Capecitabine

6 (6.1)

1 (4.2)

    

Radiological response to preoperative chemotherapyg

 PR

57 (58.8)

13 (54.2)

0.683

   

 SD

30 (30.9)

7 (29.2)

    

 PD

10 (10.3)

4 (16.7)

    
  1. ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score, PD progressive disease, PR partial response, SD stable disease
  2. aData were available for 243 patients
  3. bData were available for 238 patients
  4. cData were available for 260 patients
  5. dData were available for 251 patients
  6. eData were available for 243 patients
  7. fData were available for 225 patients
  8. gData were available for 121 patients
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us